Faron Pharmaceuticals Oy (LON:FARN – Get Free Report)’s stock price reached a new 52-week low on Wednesday. The stock traded as low as GBX 30.06 and last traded at GBX 32.25, with a volume of 74,224 shares changing hands. The stock had previously closed at GBX 31.50.
Faron Pharmaceuticals Oy Stock Up 4.4%
The company has a debt-to-equity ratio of 154.15, a current ratio of 2.40 and a quick ratio of 1.09. The company has a market cap of £66.75 million, a price-to-earnings ratio of -2.86 and a beta of 1.12. The firm has a 50-day moving average price of GBX 36.21 and a 200 day moving average price of GBX 55.30.
About Faron Pharmaceuticals Oy
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Featured Articles
- Five stocks we like better than Faron Pharmaceuticals Oy
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
